Anti-Thrombin Test for Clotting Disorders at Chughtai Lab

Anti-Thrombin Test at Chughtai Lab

The Anti-Thrombin test, specifically measuring Antithrombin III (AT III) activity or antigen levels, is a highly specialized coagulation assay performed to evaluate a patient’s risk of developing abnormal blood clots. Antithrombin is a critical glycoprotein produced primarily by the liver. It serves as a natural anticoagulant within the human body, regulating the coagulation cascade by neutralizing several key clotting enzymes, most notably thrombin (Factor IIa) and activated Factor X (Factor Xa), as well as Factors IXa, XIa, and XIIa. Under normal physiological conditions, antithrombin maintains a delicate balance, preventing the blood from clotting excessively while still allowing normal clot formation during vascular injury. When antithrombin levels or functional activity are deficient, this balance is disrupted, leading to a state of hypercoagulability or thrombophilia, which significantly increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE).

At Chughtai Lab, Pakistan’s premier diagnostic network, the Anti-Thrombin test is performed using advanced automated coagulation analyzers that utilize state-of-the-art chromogenic and immunoturbidimetric methodologies. These advanced technologies ensure the highest degree of analytical sensitivity and specificity, allowing clinical pathologists to distinguish between quantitative deficiencies (Type I) and qualitative defects (Type II) of the antithrombin protein. Evaluating antithrombin is of paramount clinical importance in patients presenting with unexplained, recurrent thromboembolic events, those with a strong family history of thrombophilia, and individuals showing resistance to standard heparin therapy. By providing precise, evidence-based measurements, Chughtai Lab assists hematologists, cardiologists, obstetricians, and vascular specialists across Pakistan in establishing accurate diagnoses, tailoring anticoagulant therapies, and implementing preventive strategies for high-risk patients.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is vital to ensure the clinical accuracy of coagulation studies like the Anti-Thrombin test. Because various medications and physiological states can profoundly influence antithrombin levels, patients must adhere to the following guidelines:

• Medication Disclosure: Patients must inform their prescribing physician and the Chughtai Lab staff of all medications they are currently taking, especially anticoagulants such as unfractionated heparin, low-molecular-weight heparin (LMWH), warfarin, or direct oral anticoagulants (DOACs) like rivaroxaban and apixaban.
• Timing Relative to Anticoagulant Therapy: Heparin therapy can transiently decrease antithrombin levels. Therefore, it is clinically recommended to perform the test at least 48 to 72 hours after discontinuing heparin therapy, unless the test is specifically ordered to investigate heparin resistance. Similarly, oral anticoagulant therapy (like warfarin) should ideally be discontinued for at least two weeks prior to testing, under strict medical supervision, to avoid confounding results.
• Timing Relative to Acute Clotting Events: Antithrombin levels are often consumed and temporarily depleted during an acute thrombotic event (such as an active DVT or PE). To obtain an accurate baseline, especially when screening for hereditary deficiency, testing should ideally be delayed for 4 to 6 weeks after the acute episode has resolved and anticoagulant therapy has ceased.
• Fasting Requirements: While strict fasting is generally not mandatory for an isolated antithrombin test, a light fast of 4 to 6 hours is often recommended to prevent lipemia (excess fat in the blood), which can interfere with the optical detection systems used in automated coagulation analyzers.
• Hydration: Patients are encouraged to drink plenty of water before the procedure to ensure adequate hydration, which facilitates easier venous access.

During the Procedure

The Anti-Thrombin test is a standard venipuncture procedure performed by highly trained phlebotomists at Chughtai Lab collection centers or through their convenient home sample collection service. The procedure involves the following steps:

• Patient Identification and Verification: The phlebotomist verifies the patient’s identity using multiple identifiers and reviews the clinical history, noting any active anticoagulant therapies.
• Positioning: The patient is seated comfortably, and the arm is extended and supported.
• Vein Selection and Sanitization: A tourniquet is briefly applied to the upper arm to locate a suitable vein, typically in the antecubital fossa. The site is thoroughly sanitized with an antiseptic swab and allowed to air dry.
• Venipuncture and Sample Collection: A sterile, single-use needle is inserted into the vein. The blood is collected directly into a light blue-top tube containing buffered sodium citrate (3.2%). This specific anticoagulant is essential for coagulation testing as it reversibly binds calcium, preserving the clotting factors in an inactive state.
• Tube Filling and Mixing: The tube must be filled to its precise fill line to maintain the critical 9:1 ratio of blood to liquid anticoagulant. Immediately after collection, the phlebotomist gently inverts the tube 3 to 4 times to ensure thorough mixing of the blood with the sodium citrate, preventing micro-clot formation.
• Post-Puncture Care: The needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball to prevent hematoma formation. A bandage is then applied.
• Sample Transport: The citrated blood sample is promptly transported to the central processing laboratory under controlled temperature conditions, where it undergoes centrifugation to obtain platelet-poor plasma for analysis.

When is an Anti-Thrombin Test Performed?

Evaluating Unexplained Blood Clots (Thrombophilia)

Physicians frequently request an Anti-Thrombin test when a patient experiences unexplained or recurrent blood clots, particularly at a young age (under 50 years). Venous thromboembolism occurring without obvious provoking factors—such as major surgery, prolonged immobilization, or severe trauma—strongly suggests an underlying hypercoagulable state. Testing helps identify whether a hereditary or acquired antithrombin deficiency is the primary driver of these thrombotic events, allowing clinicians to make informed decisions regarding the duration and intensity of long-term anticoagulant therapy.

Investigating Recurrent Pregnancy Loss

Antithrombin deficiency is a recognized risk factor for obstetric complications, including recurrent pregnancy loss, unexplained late-term fetal demise, severe preeclampsia, and intrauterine growth restriction (IUGR). During pregnancy, the maternal body naturally shifts toward a hypercoagulable state to prevent excessive bleeding during delivery. However, if an underlying antithrombin deficiency exists, microthrombi can form within the placental vasculature, compromising fetal blood supply. Obstetricians order this test as part of a comprehensive thrombophilia panel to identify high-risk patients who may benefit from prophylactic low-molecular-weight heparin therapy during gestation.

Monitoring Heparin Resistance

Unfractionated heparin exerts its anticoagulant effect by binding to antithrombin, accelerating its natural inhibitory activity against thrombin and Factor Xa by over 1,000-fold. In patients with severely depleted antithrombin levels, standard doses of heparin fail to achieve the desired therapeutic prolongation of the activated partial thromboplastin time (aPTT). This clinical phenomenon, known as heparin resistance, is frequently encountered in patients undergoing cardiopulmonary bypass surgery, extracorporeal membrane oxygenation (ECMO), or treatment for massive thrombosis. Performing an Anti-Thrombin test allows critical care specialists to diagnose this resistance and adjust therapy, sometimes administering antithrombin concentrates or alternative anticoagulants.

Diagnosing Acquired Antithrombin Deficiency

Acquired antithrombin deficiency can arise from several non-hereditary medical conditions that affect the protein’s synthesis, loss, or consumption. Because antithrombin is synthesized in the liver, severe hepatic disorders such as cirrhosis, acute liver failure, or liver congestion can significantly impair its production. Additionally, renal diseases like nephrotic syndrome can lead to the pathological excretion of antithrombin in the urine. Critical care physicians also utilize this test to diagnose and monitor Disseminated Intravascular Coagulation (DIC), a life-threatening condition characterized by widespread systemic clotting that rapidly consumes available antithrombin.

Screening Family Members with Hereditary Thrombophilia

Hereditary antithrombin deficiency is an autosomal dominant genetic disorder, meaning there is a 50% chance of passing the mutation to offspring. When a patient is diagnosed with a hereditary deficiency, hematologists often recommend screening close biological relatives, even if they are currently asymptomatic. Identifying asymptomatic carriers is highly beneficial, as it allows healthcare providers to implement temporary prophylactic measures during high-risk scenarios, such as major orthopedic surgeries, prolonged travel, pregnancy, or postpartum recovery, thereby preventing potentially life-threatening thrombotic events.

What Does an Anti-Thrombin Test Detect?

The Anti-Thrombin test is highly sensitive and capable of detecting a wide range of hereditary and acquired clinical conditions. Specifically, the test detects and helps differentiate:

• Hereditary Antithrombin Deficiency Type I: Characterized by a quantitative reduction in both the functional activity and the actual physical amount (antigen) of the antithrombin protein in circulation.
• Hereditary Antithrombin Deficiency Type II: Characterized by normal or near-normal antigen levels of the protein, but significantly reduced functional activity due to structural abnormalities in the heparin-binding site or the reactive site.
• Acquired Deficiency due to Hepatic Dysfunction: Reduced synthesis of antithrombin resulting from chronic liver diseases, cirrhosis, or acute liver failure.
• Nephrotic Syndrome: Excessive renal loss of antithrombin through damaged glomerular basements, resulting in systemic depletion and a high risk of renal vein thrombosis.
• Disseminated Intravascular Coagulation (DIC): Rapid, widespread consumption of antithrombin as it attempts to neutralize massive amounts of thrombin generated during systemic inflammatory states or sepsis.
• Active Thrombus Consumption: Temporary depletion of antithrombin during acute, extensive deep vein thrombosis or massive pulmonary embolism.
• Heparin-Induced Depletion: A transient decrease in circulating antithrombin levels caused by prolonged or high-dose unfractionated heparin therapy.
• L-Asparaginase Therapy Effects: Reduced hepatic synthesis of antithrombin in leukemia patients undergoing treatment with L-asparaginase.
• Estrogen-Induced Alterations: Mild to moderate decreases in antithrombin activity associated with high-dose oral contraceptive use or hormone replacement therapy.
• Pregnancy-Related Fluctuations: Physiological decreases in antithrombin levels that can occur during late pregnancy or the immediate postpartum period.
• Neonatal Physiological Lows: Naturally lower levels of antithrombin in healthy newborns and infants, which gradually rise to adult levels by six months of age.
• Sepsis and Severe Inflammatory States: Impaired synthesis and accelerated degradation of antithrombin mediated by pro-inflammatory cytokines.
• Microangiopathic Hemolytic Anemias: Consumption of coagulation inhibitors in conditions like thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS).
• Severe Burn Injury Consumption: Depletion of antithrombin due to capillary leakage and systemic inflammatory response syndrome (SIRS) following major thermal trauma.
• Major Surgical Consumption: Transient drops in antithrombin levels following extensive surgical procedures due to blood loss, hemodilution, and localized clotting activation.
• Malnutrition and Cachexia: Decreased protein synthesis leading to generalized deficiencies in coagulation inhibitors.
• Protein-Losing Enteropathy: Pathological loss of antithrombin through the gastrointestinal tract.
• Cardiopulmonary Bypass Consumption: Depletion of antithrombin resulting from the activation of coagulation pathways by extracorporeal circuits.
• Normal Coagulation Balance: Normal antithrombin activity, which helps rule out antithrombin deficiency as the cause of a patient’s thrombotic symptoms, directing clinicians to investigate other factors like Factor V Leiden or Antiphospholipid Syndrome.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized for its commitment to providing rapid turnaround times (TAT) without compromising clinical accuracy. For specialized coagulation assays like the Anti-Thrombin test, samples are processed in centralized, high-throughput laboratories equipped with advanced cold-chain logistics to preserve sample integrity. Typically, the verified test results are available within 24 to 48 hours of sample collection.

Patients and referring physicians can access reports seamlessly through multiple digital channels. Chughtai Lab offers an online patient portal on its official website, where reports can be viewed and downloaded using the patient’s lab number and password. Additionally, the user-friendly My Chughtai App allows patients to track their sample status, view historical lab reports, and share results directly with their healthcare providers. For added convenience, automated PDF reports are sent via WhatsApp and email as soon as they are finalized and verified by a consultant hematologist.

Anti-Thrombin Findings Overview

Parameter / Condition Evaluated	Normal Findings	Possible Abnormal Findings & Clinical Significance
Antithrombin III Activity (Functional)	80% to 120% of normal human plasma activity	< 80%: Increased risk of thrombosis, heparin resistance, hereditary or acquired deficiency. > 120%: Generally of limited clinical significance; may occur in acute phase reactions.
Antithrombin III Antigen (Quantitative)	22 to 39 mg/dL (may vary slightly by assay)	Decreased: Confirms Type I hereditary deficiency or acquired depletion (liver disease, nephrotic syndrome). Normal with low activity: Suggests Type II qualitative deficiency.
Heparin Resistance Evaluation	Normal response to heparin anticoagulation	Low antithrombin levels prevent heparin from exerting its therapeutic effect, requiring alternative anticoagulants or AT concentrates.
Liver Function Context	Normal synthesis of coagulation proteins	Significantly reduced antithrombin levels in patients with cirrhosis or liver failure, reflecting impaired hepatic synthetic capacity.
Renal Filtration Status	No significant protein loss in urine	Markedly decreased systemic antithrombin levels in nephrotic syndrome due to urinary protein loss, increasing the risk of thromboembolism.
Disseminated Intravascular Coagulation (DIC)	Stable coagulation inhibitor levels	Severely depleted antithrombin levels due to rapid, systemic consumption during uncontrolled coagulation activation.
Pregnancy & Postpartum	Mild physiological decrease (usually remains > 75%)	Significant drops (< 70%) during pregnancy indicate a high risk of placental thrombosis, preeclampsia, or fetal loss.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Anti-Thrombin Testing?

• Experienced Healthcare Professionals: Chughtai Lab’s hematology department is led by highly qualified consultant pathologists and hematologists who oversee all coagulation testing and provide expert clinical interpretations.
• ISO 15189 Certified Laboratories: The laboratory operates under strict international quality standards, ensuring that all coagulation assays meet rigorous global benchmarks for accuracy and reliability.
• State-of-the-Art Automated Analyzers: Chughtai Lab utilizes advanced, fully automated coagulation systems that minimize human error and deliver highly precise functional and quantitative measurements.
• Convenient Home Sample Collection: Patients can have their blood samples drawn in the comfort of their homes by professionally trained phlebotomists, maintaining strict sample handling protocols.
• Extensive National Network: With hundreds of collection centers across Pakistan, including major hubs in Lahore, Karachi, Islamabad, and Peshawar, Chughtai Lab offers unmatched accessibility.
• Robust Cold-Chain Logistics: Specialized coagulation samples are transported under strictly monitored temperature conditions to prevent pre-analytical degradation of sensitive clotting factors.
• Seamless Digital Report Access: Patients can easily retrieve their reports via the My Chughtai App, official website, WhatsApp, or email, ensuring prompt clinical decision-making.
• Commitment to Accurate Diagnosis: Chughtai Lab’s dedication to quality control, regular proficiency testing, and patient-centric care ensures that every test result is highly trustworthy and clinically actionable.